Q-omics provides the consensus-scored TYROBP profile across patient tissues and cancer cell-line models. TYROBP expression is associated with patient survival in 23 of 34 cancer types, with the highest sampling consensus in UVM. Among the 18 cancer types available for tumor–normal comparison, TYROBP is differentially expressed in 9, with the highest sampling consensus in KIRC. Additionally, TYROBP protein abundance shows 28,996 significant protein co-abundance associations, with the highest sampling consensus in LSCC. Together, these results highlight UVM, KIRC, and LSCC as cancer lineages where TYROBP shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for TYROBP — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes TYROBP survival associations across molecular data types. TYROBP RNA expression shows survival associations in the most cancer types (23), followed by mutation status (4) and mass-spec protein abundance (10). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible TYROBP RNA expression–survival associations across cancer types. High TYROBP expression shows unfavorable associations in UVM, LGG and ACC, but favorable associations in SKCM, CESC and HNSC. The UVM Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify UVM as the clearest survival context for TYROBP RNA expression.
This table summarizes TYROBP tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 9, while mass-spec protein shows differences in 9. The strongest signals are observed in KIRC for RNA and CCRCC for protein.
This table ranks reproducible tumor–normal expression differences for TYROBP. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. TYROBP shows lower tumor expression in LUAD and LUSC and higher tumor expression in KIRC, KIRP, THCA and HNSC. The KIRC box plot shows higher TYROBP RNA expression in tumor versus normal tissue (log2 FC = +3.080, t-test p < 0.001).
This table shows molecular features associated with TYROBP in patient tissues and cancer cell lines. In patient samples, TYROBP shows the broadest associations at the RNA and protein expression levels, with LSCC recurring as the lineage with the largest associated feature set. In cancer cell lines, TYROBP RNA and mutation anchors are most strongly linked to RNA-expression features, especially in CNS, while CRISPR and shRNA rows add functional-dependency signals in BLOOD_Leukemia and BLOOD_Myeloma.
